Boston Scientific (NYSE: BSX) reported Q3 EPS of $0.37, $0.12 better than the analyst estimate of $0.25. Revenue for the quarter came in at $2.67 billion versus the consensus estimate of $2.52 billion.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.